The antibody is an FDA-approved agent for RA, NOMID, and DIRA. Due to the blockade of IL-1 pathway, Anakinra was applied to treat CVD. Clinical trial showed that it reduced hsCRP levels after 14-d treatment with higher risk of MACEs at 1 year in the patients with NSTE-ACS. Another trial reported that Anakinra lowered hsCRP levels and incidence of new-onset heart failure in patients with STEMI. Here, IL1A is linked to rheumatoid arthritis.